Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Appl Microbiol Biotechnol ; 102(1): 211-223, 2018 Jan.
Article in English | MEDLINE | ID: mdl-29082420

ABSTRACT

Polyunsaturated fatty acids (PUFAs) are essential lipids for cell function, normal growth, and development, serving as key structural components of biological membranes and modulating critical signal transduction events. Omega-3 (n-3) long chain PUFAs (LC-PUFAs) such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have been shown to protect against inflammatory diseases and enhance brain development and function. This had led to a marked increase in demand for fish and fish oils in human diets, supplements, and aquaculture and created a need for new, sustainable n-3 LC-PUFA sources. We have studied for the first time homogenous preparations of the membrane-type ω6 and ω3 fatty acid desaturases from the fungus Mortierella alpina, as a model system to produce PUFAs. These desaturases possess a di-iron metal center and are selective for 18:1 n-9 and 18:2 n-6 acyl-CoA substrates, respectively. Sequence alignments and membrane topology predictions support that these enzymes have unique cap regions that may include the rearrangement and repositioning of the active site, especially when compared to the mammalian stearoyl-coenzyme A desaturase-1 (SCD1) and the related sphingolipid α-hydroxylase (Scs7p) that act upon different substrates.


Subject(s)
Fatty Acid Desaturases/chemistry , Fatty Acid Desaturases/metabolism , Fatty Acids, Unsaturated/biosynthesis , Mortierella/enzymology , Amino Acid Sequence , Cytochrome-B(5) Reductase/genetics , Cytochrome-B(5) Reductase/isolation & purification , Cytochrome-B(5) Reductase/metabolism , Cytochromes b/genetics , Cytochromes b/isolation & purification , Cytochromes b/metabolism , Fatty Acid Desaturases/genetics , Fatty Acid Desaturases/isolation & purification , Fatty Acids, Omega-3/metabolism , Fatty Acids, Omega-6/metabolism , Humans , Iron/chemistry , Kinetics , Membranes/chemistry , Membranes/enzymology , Mortierella/classification , Mortierella/genetics , Phylogeny , Substrate Specificity
2.
Biochim Biophys Acta ; 1862(2): 233-9, 2016 02.
Article in English | MEDLINE | ID: mdl-26655602

ABSTRACT

Excessive endogenous oxalate synthesis can result in calcium oxalate kidney stone formation and renal failure. Hydroxyproline catabolism in the liver and kidney contributes to endogenous oxalate production in mammals. To quantify this contribution we have infused Wt mice, Agxt KO mice deficient in liver alanine:glyoxylate aminotransferase, and Grhpr KO mice deficient in glyoxylate reductase, with (13)C5-hydroxyproline. The contribution of hydroxyproline metabolism to urinary oxalate excretion in Wt mice was 22±2%, 42±8% in Agxt KO mice, and 36%±9% in Grhpr KO mice. To determine if blocking steps in hydroxyproline and glycolate metabolism would decrease urinary oxalate excretion, mice were injected with siRNA targeting the liver enzymes glycolate oxidase and hydroxyproline dehydrogenase. These siRNAs decreased the expression of both enzymes and reduced urinary oxalate excretion in Agxt KO mice, when compared to mice infused with a luciferase control preparation. These results suggest that siRNA approaches could be useful for decreasing the oxalate burden on the kidney in individuals with Primary Hyperoxaluria.


Subject(s)
Alcohol Oxidoreductases/genetics , Hydroxyproline/metabolism , Hyperoxaluria, Primary/genetics , Hyperoxaluria, Primary/therapy , Proline Oxidase/metabolism , RNAi Therapeutics , Alcohol Oxidoreductases/metabolism , Animals , Disease Models, Animal , Hyperoxaluria, Primary/metabolism , Liver/enzymology , Liver/metabolism , Male , Mice , Mice, Inbred C57BL , Oxalates/metabolism , RNA, Small Interfering/genetics , RNA, Small Interfering/therapeutic use , RNAi Therapeutics/methods
3.
Biochim Biophys Acta ; 1852(12): 2700-5, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26428388

ABSTRACT

Primary Hyperoxaluria Type 3 is a recently discovered form of this autosomal recessive disease that results from mutations in the gene coding for 4-hydroxy-2-oxoglutarate aldolase (HOGA1). This enzyme is one of the 2 unique enzymes in the hydroxyproline catabolism pathway. Affected individuals have increased urinary excretions of oxalate, 4-hydroxy-L-glutamate (4-OH-Glu), 4-hydroxy-2-oxoglutarate (HOG), and 2,4-dihydroxyglutarate (DHG). While 4-OH-Glu and HOG are precursor substrates of HOGA1 and increases in their concentrations are expected, how DHG is formed and how HOG to oxalate are unclear. To resolve these important questions and to provide insight into possible therapeutic avenues for treating this disease, an animal model of the disease would be invaluable. We have developed a mouse model of this disease which has null mutations in the Hoga1 gene and have characterized its phenotype. It shares many characteristics of the human disease, particularly when challenged by the inclusion of hydroxyproline in the diet. An increased oxalate excretion is not observed in the KO mice which may be consistent with the recent recognition that only a small fraction of the individuals with the genotype for HOGA deficiency develop PH.

SELECTION OF CITATIONS
SEARCH DETAIL
...